Qnovia
Qnovia is a platform pharmaceutical company dedicated to saving lives through innovative inhaled drug delivery technology. Their mission is to develop effective inhaled therapies, including nicotine cessation products, to address major health issues such as smoking. They aim to redefine inhaled drug delivery by partnering with leading healthcare companies to improve efficacy and patient compliance. The company has rebranded from Respira Technologies and is actively pursuing FDA and UK MHRA approvals for their products, with a focus on smoking cessation therapies like RespiRx™ Nicotine Inhaler. Qnovia has secured significant funding and is involved in clinical trials and strategic growth initiatives, positioning itself as a key player in inhaled therapeutics.
Industries
Nr. of Employees
small (1-50)
Qnovia
Patents
Electronic devices for aerosolizing and inhaling liquid having an enclosed interior air passageway with diaphragm and pressure sensor
US-12279650-B2
View DetailsElectronic devices for aerosolizing and inhaling liquid having diaphragm and a pressure sensor
US-11925207-B2
View Details
Electronic devices for aerosolizing and inhaling liquid having an enclosed interior air passageway with diaphragm and pressure sensor
US-12279650-B2
View DetailsElectronic devices for aerosolizing and inhaling liquid having diaphragm and a pressure sensor
US-11925207-B2
View DetailsProducts
Prescription inhaled nicotine replacement therapy (nicotine inhaler)
A cartridge-based prescription inhaler designed to deliver nicotine via inhalation with metered dosing, device-based prompts and digital tracking to support smoking cessation.
Inhaled drug delivery technology platform
A platform that combines device engineering, delivery mechanics, and digital dosing management to enable development of inhalable therapies for multiple compounds and indications.
Prescription inhaled nicotine replacement therapy (nicotine inhaler)
A cartridge-based prescription inhaler designed to deliver nicotine via inhalation with metered dosing, device-based prompts and digital tracking to support smoking cessation.
Inhaled drug delivery technology platform
A platform that combines device engineering, delivery mechanics, and digital dosing management to enable development of inhalable therapies for multiple compounds and indications.
Services
Partnership-based development services to advance inhalable therapies combining device engineering, formulation considerations, and clinical and regulatory support.
Execution of first-in-human and Phase I pharmacokinetic and safety studies for inhalation therapies, including device-related clinical endpoints and PK analysis.
Support for preparation and management of regulatory filings and interactions with agencies, including IND submissions and national regulatory pathways.
Advisory and execution support for market entry, commercial partnerships and region-specific commercialization planning.
Partnership-based development services to advance inhalable therapies combining device engineering, formulation considerations, and clinical and regulatory support.
Execution of first-in-human and Phase I pharmacokinetic and safety studies for inhalation therapies, including device-related clinical endpoints and PK analysis.
Support for preparation and management of regulatory filings and interactions with agencies, including IND submissions and national regulatory pathways.
Advisory and execution support for market entry, commercial partnerships and region-specific commercialization planning.
Expertise Areas
- Inhalation drug delivery
- Drug-device combination development
- Early-phase clinical development (first-in-human / Phase I)
- Regulatory submissions and agency engagement (IND and national approvals)
Key Technologies
- Aerosol generation for inhalation
- Cartridge-based inhaler systems
- Breath-actuated inhaler mechanisms
- Metered dosing mechanisms
News & Updates
Qnovia announced leadership changes to support its UK market expansion.
First patient in the US has been dosed in a Phase 1 trial for their nicotine inhaler.
The company secured $16 million to fund its inhaled therapeutics pipeline.
An article discussing Qnovia's innovative approach to smoking cessation.
Received FDA approval for their nicotine inhaler product.
Qnovia announced leadership changes to support its UK market expansion.
First patient in the US has been dosed in a Phase 1 trial for their nicotine inhaler.
The company secured $16 million to fund its inhaled therapeutics pipeline.
An article discussing Qnovia's innovative approach to smoking cessation.
Received FDA approval for their nicotine inhaler product.